Navigation Links
Inovio Pharmaceuticals Reports 2011 Third Quarter Financial Results
Date:11/7/2011

BLUE BELL, Pa., Nov. 7, 2011 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE AMEX: INO) today reported financial results for the quarter ended September 30, 2011.

Total revenue was $2.6 million and $8.2 million for the three and nine months ended September 30, 2011, compared to $1.3 million and $3.8 million for the same periods in 2010.

Total operating expenses for the three and nine months ended September 30, 2011, were $9.0 million and $24.0 million as compared to $5.8 million and $17.7 million for the same periods in 2010.

The net loss attributable to common stockholders for the three and nine months ended September 30, 2011, was $4.5 million, or $0.04 per share, and $9.8 million, or $0.08 per share, as compared with a net loss attributable to common stockholders of $1.4 million, or $0.01 per share, and $11.3 million, or $0.11 per share, for the three and nine months ended September 30, 2010.

Revenue The increase in revenue for the three and nine months ended September 30, 2011, as compared with the same periods in 2010, was primarily due to an increase in revenue from the company's contract with the National Institute of Allergy and Infectious Diseases ("NIAID"). This contract revenue amounted to $1.9 million and $6.4 million for the three and nine months ended September 30, 2011, as compared with $895,000 and $2.7 million for the same periods in 2010. This NIAID HIV Vaccine Design and Development Teams contract, which exceeds $23 million over five years (plus two additional option years), is facilitating Inovio's development of a universal, preventive HIV DNA vaccine, PENNVAX™-GP, focused on providing coverage against a broad set of global HIV clades, or sub-types.

Operating Expenses Research and development expenses for the three and nine months ended September 30, 2011, were $7.0 million and $15.9 million as compared to $3.0 m
'/>"/>

SOURCE Inovio Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Inovio Pharmaceuticals Closes $24.3 Million Registered Offering
2. University of Southampton and Inovio Pharmaceuticals Initiate Phase 2 Clinical Study to Evaluate Leukemia DNA Vaccine Using Electroporation Delivery Technology
3. Inovio Pharmaceuticals Dual-Antigen SynCon™ DNA Vaccine for Prostate Cancer Induces Robust Responses in Preclinical Trial
4. Inovio Pharmaceuticals Unveils Needle-free, Contactless Electroporation Technology for DNA Vaccine Delivery
5. Inovio Pharmaceuticals to Present at Partnering and Scientific Conferences
6. Inovio Pharmaceuticals to Present at Cowen & Co. Health Care Conference
7. Inovio Pharmaceuticals to Present at ROTH 23rd Annual Growth Stock Conference
8. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
9. OncoSec Medical Licenses Non-DNA Vaccine Tumor Therapy Technology from Inovio Pharmaceuticals
10. Inovio Pharmaceuticals Licenses Non-DNA Vaccine Tumor Therapy Technology to OncoSec Medical
11. Inovio Pharmaceuticals Reports 2010 Fourth Quarter and Year End Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Aug. 20, 2014 ApolloDx™ today announced it ... during a special event at the company,s office in ... September 5, 2014. The event, which will start at ... website, www.apollodx.com .    "We believe ... Jared Bauer , Co-Founder and Managing Partner of ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... its catalogue: Global Feminine Hygiene Products Industry ... report analyzes the worldwide markets for Feminine Hygiene Products ... Pads/Towels, Tampons, Panty liners, and Others. The report provides ... , Japan , ...
(Date:8/20/2014)... , Aug. 20, 2014  Glades Drugs, an independent ... is proud to announce its expansion into a new corporate ... will feature an 8,000-square-foot office space and state of the ... applications for 100 open positions for the new facility. ... Lantana Road will serve as the chain,s corporate headquarters and ...
Breaking Medicine Technology:Global Feminine Hygiene Products Industry 2Global Feminine Hygiene Products Industry 3Global Feminine Hygiene Products Industry 4Global Feminine Hygiene Products Industry 5Global Feminine Hygiene Products Industry 6Global Feminine Hygiene Products Industry 7Global Feminine Hygiene Products Industry 8Global Feminine Hygiene Products Industry 9Global Feminine Hygiene Products Industry 10Global Feminine Hygiene Products Industry 11Global Feminine Hygiene Products Industry 12Global Feminine Hygiene Products Industry 13Global Feminine Hygiene Products Industry 14Global Feminine Hygiene Products Industry 15Global Feminine Hygiene Products Industry 16Global Feminine Hygiene Products Industry 17Global Feminine Hygiene Products Industry 18Global Feminine Hygiene Products Industry 19Global Feminine Hygiene Products Industry 20Global Feminine Hygiene Products Industry 21Global Feminine Hygiene Products Industry 22Global Feminine Hygiene Products Industry 23Global Feminine Hygiene Products Industry 24Global Feminine Hygiene Products Industry 25Global Feminine Hygiene Products Industry 26Glades Drugs Moves to New Corporate Headquarters, 100 Open Positions 2
... Data from Serial Outpatient Infusion Study in Patients ... of Cardiology 56th Annual Scientific Session --, MOUNTAIN ... -- Scios Inc. announced today that an exploratory,920-patient, ... effect on the primary endpoint, a composite of ...
... March 26, 2007 /PRNewswire/ -- A large ... CYPHER(R) Sirolimus-eluting,Coronary Stent reported favorable safety and ... investigators at the of,Cardiology's 56th Annual Scientific ... a prospective, single-arm study designed,to evaluate the ...
Cached Medicine Technology:Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 2Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 3Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 4Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 5Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 6Scios Announces Results From Exploratory Nesiritide Study Providing,Important New Renal and Mortality Safety Data with a Neutral Effect,on the Primary Endpoint 7Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 2Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 3Two-Year Patient Registry Results Support Safety and Efficacy of,Cypher Sirolimus-Eluting Coronary Stent in 'Real World' Uses 4
(Date:8/20/2014)... August 20, 2014 The report ... Cars - A Global Analysis: by Geography - ... MarketsandMarkets, classifies and defines automotive airbag and seatbelt ... report highlights potential growth opportunities in the coming ... – market drivers, restrains, growth indicators, challenges, legislation ...
(Date:8/20/2014)... 2014 In a recent article published ... College London (UCL) study showed that dental experts from ... brushing teeth was the most effective. Analysis of 66 ... techniques were frequently recommended, but none were favored by ... Dentistry, experienced cosmetic dentist Dr. Patrick J. ...
(Date:8/20/2014)... August 20, 2014 Hope For The ... Hope® Celebration to be hosted in Washington, DC on ... Club. This signature event honors the courage of our ... the fallen. Proceeds from the Got Heart, Give Hope® ... nonprofit dedicated to restoring a sense of self, restoring ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 No matter how ... count on a steady set of friends to be always ... it comes to the concept of making new friends ... various responsibilities ranging from taking care of one’s family to ... with talking to a new person just is not the ...
(Date:8/20/2014)... Ticketability.com has Theresa Caputo tickets ... The well-known medium has been thrilling many with her ... 19 cities, with tickets becoming available August 15. , ... are Albany, Baltimore, Trenton, Erie, Buffalo, Philadelphia, Charlotte, Houston, ... San Diego. The medium’s fans can obtain Theresa Caputo ...
Breaking Medicine News(10 mins):Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 2Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 3Health News:Automotive Airbag Market Worth $23.6 Billion and Automotive Seat Belt Market Worth $9.0 Billion by 2019 – New Report by MarketsandMarkets 4Health News:Ending Confusion About the Best Way to Brush Teeth 2Health News:Ending Confusion About the Best Way to Brush Teeth 3Health News:Hope For The Warriors Announces Got Heart, Give Hope Celebration in Washington, DC 2Health News:‘How to Make Friends as an Adult by Just Being Yourself: Becoming a “People Person” In Three Steps or Less’ Gives Tips for Making Friends During Adulthood - Vinamy 2Health News:Theresa Caputo Tour Tickets for Sale at Ticketability.com Cause a Buying Frenzy Among Customers Over Their Offering of Deeply Discounted Seats 2
... a new study, people with Down syndrome live twice as long ... a lower than average risk of developing many forms of cancer. ... week's Lancet was based on data collected from death certificates between ... average age at death for the 10,800 reported to have Down ...
... memory loss is often an indicator of Alzheimer's disease and is ... of controversy over the implications of mild cognitive decline the loss ... solving and planning.Some people think it is a normal part of ... while there is also the view that it's a disease in ...
... side of the brain helps people recognise themselves in ... Beth Israel Deaconess Medical Center in Boston report their ... study joins a growing body of evidence that demonstrates ... Studies of self-awareness may provide unique insights into consciousness ...
... to drink more to feel drunk than non-smoking drinkers – ... livers and hearts, a new study suggests.// ,The study ... are considered a good model for humans.Since alcohol abusers generally ... to get an expected level of intoxication, say the researchers ...
... a potential new treatment for people with severe cases of ... involves removing stem cells// from the patients’ blood, killing the ... then returning the healthy cells back to the body. The ... healthy immune system cells and the disease process can be ...
... People who take the cholesterol-lowering drugs called statins may ... 80%. Statins have been proved to offer// powerful protection ... The findings provide the strongest evidence to date that ... disease. ,An earlier, smaller study had suggested ...
Cached Medicine News:Health News:Down syndrome life anticipation doubles 2Health News:Right side of the brain helps in awareness 2
... Laser System is a solid state Holmium: ... in all areas of the urinary tract, ... , ,A variety of reusable fibers provide ... clinical versatility and outcomes. Standard 115V electrical ...
... offers increased bone surface area contact between ... management of nonunions in long bones., ,Grid-Like ... of Contact on Host Bone , ,The ... cathode offers increased surface area and a ...
... proud to offer one of ... market at only 188 grams! ... a superior flow rate with ... mechanisms. The complementing electrodes provide ...
Flowmate makes portable uroflowmetry easy, accurate and dignified. Flowmate has automatic start and stop as well as simple and straightforward reporting from its own printer....
Medicine Products: